Franck Gallardo, et al. Biomedicines, November 26 2020 – Read the article Publication
Month: November 2020
Detailed results of the Phase 1b/2 trial of TG4001 and avelumab in advanced HPV-positive cancers presented at SITC 2020
Link to webcast
Transgene and BioInvent present data on next generation oncolytic virus BT-001 at the SITC 35th Anniversary Annual Meeting
20201109 Transgene BioInvent_SITC BT001_EN
Transgene presents e-poster outlining detailed results from the Phase 1b/2 trial of TG4001 in combination with avelumab in advanced HPV-positive cancers at SITC 2020
20201109 – TG4001+avelumab presentation poster SITC – EN
BT-001, an oncolytic vaccinia virus armed with a Treg-depleting human recombinant anti-CTLA4 antibody and GM-CSF to target the tumor microenvironment
Poster BT-001 M. Semmrich et al. SITC 2020 Download the poster here Poster Presentation
TG4001 (Tipapkinogene sovacivec) and avelumab for recurrent/metastatic (R/M) Human Papilloma Virus (HPV)-16+ cancers: clinical efficacy and immunogenicity
Poster SITC TG4001 C. Le Tourneau et al. SITC 2020 Download the poster here Poster Presentation
Transgene reports business update and end Q3 2020 financial position
20201105 Transgene Q3 business upradta EN
Transgene Presents its Individualized Immunotherapy, TG4050, at the Annual Neoantigen Based Therapies Summit
20201105 TG – Neoantigen summit presentation